AMGN · Amgen
AI read · Good for AMGN
The AI's read
The sales rise came from a broad group of medicines, not just one product. Amgen said its 6 key growth drivers grew 27% and made up over 70% of product sales. Three programs also had positive late-stage study results, which could support future medicine sales if development continues successfully. Amgen spent more on research and facilities, but it generated $3.7 billion in free cash flow. The broad product gains and higher company forecast make the results favorable overall.